PALO ALTO, Calif.--Incyte Pharmaceuticals announced that it has expanded its relationship with Novartis Pharma to include access to Incyte's gene expression microarray technology. The four-year agreement provides Novartis with data from pre-fabricated DNA microarrays and data from custom microarrays in exchange for access fees and per-experiment fees. Novartis will also gain access to Incyte's GEMTools software to manage and analyze the data.
Incyte and Novartis Relationship to Include Microarray Technology
Dec 18, 1998